Pfizer (PFE) Selling, General & Administrative (2009 - 2026)
Pfizer (PFE) Selling, General & Administrative (2009 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | SG&A (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 6.43 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 3.63 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 2.90 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 3.24 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 5.65 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 1.75 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 1.92 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 3.41 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -2.95 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | -2.87 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 3.41 Bn |
| Mar 29, 2026 | 2.96 Bn |
| Dec 31, 2025 | 4.16 Bn |
| Sep 28, 2025 | 3.19 Bn |
| Jun 29, 2025 | 3.42 Bn |
| Mar 30, 2025 | 3.03 Bn |
| Sep 29, 2024 | 10.46 Bn |
| Jun 30, 2024 | 3.72 Bn |
| Mar 31, 2024 | 3.50 Bn |
| Dec 31, 2023 | 4.58 Bn |
| Jul 2, 2023 | 3.50 Bn |
| Apr 2, 2023 | 3.42 Bn |
| Jul 3, 2022 | 3.05 Bn |
| Apr 3, 2022 | 2.59 Bn |
| Oct 3, 2021 | 8.60 Bn |
| Jul 4, 2021 | 2.92 Bn |
| Apr 4, 2021 | 2.78 Bn |
| Sep 27, 2020 | 7.86 Bn |
| Jun 28, 2020 | 2.66 Bn |
| Mar 29, 2020 | 2.54 Bn |